First-line tivozanib approved for use in NHS Scotland
We are delighted that the Scottish Medicines Consortium (SMC), which reviews [...]
New first-line treatment option for advanced kidney cancer available on the NHS
Today, the National Institute for Health and Care Excellence (NICE) have recommended tivozanib (Fotivda) [...]
Tivozanib plus nivolumab combination shows promise
AVEO Oncology and EUSA Pharma have announced promising results from [...]
Tivozanib approved in Europe for advanced kidney cancer
Tivozanib (Fotivda) has been approved by the European Commission (EC) [...]
NICE turns down two kidney cancer drugs
NICE has issued draft guidance this week turning down two [...]
Tivozanib given the green light by European regulators for first-line treatment of advanced kidney cancer
Tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine [...]
Tivozanib plus nivolumab combination enters phase II clinical trials
The phase I dose-escalation phase of the TiNivo trial, which [...]
First patient dosed in the TiNivo clinical trial investigating a combination of tivozanib plus nivolumab
The first patient has been dosed in the TiNivo trial: [...]
Clinical trial of tivozanib plus nivolumab combination
Tivozanib, a VEGF tyrosine kinase inhibitor, is to be combined [...]
First patient dosed in pivotal phase 3 clinical trial of tivozanib in renal cell carcinoma
AVEO Oncology has enrolled and dosed the first patient in [...]
